Elastrin Therapeutics’ Post

Lamark Biotech, a T-Angel startup is redefining the accessibility of modern medicine for under-developed areas. Most vaccines, especially for insulin, eye degeneration, and lung cancer need refrigeration and stability. Vaibhav Bhatia, CEO at Lamark Biotech talks about how the company has dedicated itself to making these medicines refrigerator-independent so that it can reach the deepest parts of the country! Watch Vaibhav talk about T-Hub's support at multiple levels from legality and due diligence to end-to-end assistance in being investment-ready! T-Hub is empowering founders and their startups. Watch here: https://bit.ly/49EMIAK #THubFounderTalks #InnovateWithThub #InnovationEcosystem

Following the FDA’s recent decision to tighten regulations for clinical laboratories, RTW Investments, LP Partner and Portfolio Manager Naveen Yalamanchi recently spoke with the The Wall Street Journal Journal’s Brian Gormley to discuss the impact this will have on lab-testing startups and the venture capital firms that invest in them. Read the full article here (subscription required): https://lnkd.in/epi7vtGm #Biotech #LDTs #Investing #Regulation

🎉 Exciting News from CyGenica: Recognized Among Top 10 Biotech Startups in India by Millionaire Backstage! 🎉 We are thrilled to announce a monumental milestone for CyGenica - being featured as one of the Top 10 Biotech Startups of India by Millionaire Backstage. This accolade is a testament to our team's relentless dedication, innovative spirit, and groundbreaking work in the biotech industry. At CyGenica, we are pioneering the future of intracellular therapeutics with our revolutionary drug delivery platform, GEENIE. Designed to transform the pharmaceutical landscape, GEENIE makes intracellular drug delivery effortless, efficient, and extraordinarily targeted. Our approach bypasses endosomes to enhance the therapeutic efficacy of drugs, representing a fundamental advancement in the field. Our achievements extend beyond this recognition. GEENIE is patented in the US and EU, and we've received top innovation awards in both India and Ireland. Furthermore, one of our drug conjugates has been granted orphan drug designation by the US FDA, underscoring our commitment to addressing unmet medical needs. This recognition by Millionaire Backstage is more than an accolade; it's a reflection of our vision, hard work, and the potential impact of our technology on patients worldwide. We are deeply grateful for this honor and motivated to continue pushing the boundaries of biotechnology. A heartfelt thank you to our incredible team, partners, and the biotech community for your support and belief in our mission. Together, we are redefining what's possible in healthcare. #CyGenica #BiotechInnovation #Top10Startups #HealthcareRevolution #GEENIE #DrugDelivery #Biotechnology

🧬🚀 Announced at the beginning of January was the "NextGen Class of 2024: Top Life Sciences Start-ups to Watch This Year" article from BioSpace. 🌐🔬 The list is determined by companies based in the US that launched between September 2022 - 2023 with Series A financing. This exciting list comprises 30 organisations that are ones to watch this year! The top 5 include: Rapport Therapeutics - launched in March 2023. Apogee Therapeutics - launched in December 2022. CARGO Therapeutics - launched in March 2023. Aera Therapeutics - launched in February 2023. Nido Biosciences - launched in May 2023. This impressive list can be found in the article linked in the comments. Excited to see what 2024 holds for these companies! #lifesciences #startups #biotech #2024

- Over the past 12 weeks, biotech startups have seen a resurgence in $100 million-plus financings, reminiscent of the market peak three years ago. - This week alone, three startups secured significant funding: Engrail Therapeutics ($157 million), Clasp Therapeutics ($150 million), and Capstan Therapeutics ($175 million). - This year has witnessed 21 companies securing nine-figure megarounds, driven partly by investors now favouring projects with clinical proof-of-concept data. - Funding for companies in clinical phases, particularly Phase 3, has risen substantially. - Biotechs, having experienced lean years, are now opting for larger rounds to sustain operations until the next fundraise. - There is ample capital available, with approximately $39.7 billion in dry powder for life sciences venture deals. - Investors are prepared for longer-term investments, anticipating potential delays in IPOs and extended periods as private companies.   Given the recent surge in megaround financings and the increasing emphasis on clinical proof-of-concept data, it will be interesting to see how this trend will shape the landscape of biotech investments going forward, particularly in terms of valuations and the likelihood of successful IPO exits.

#News: Big money is back. Over the past 12 weeks, #biotechstartups have raised $100 million-plus megarounds from #venturecapitalists at a pace that could approach the market’s peak three years ago. This week alone, three #startups announced major new financings. Engrail Therapeutics , a #neuroscience company in #Phase2, took in $157 million. Two #preclinical #biotechs, #Tcell engager player @Clasp and #invivo #CART startup Capstan Therapeutics , landed $150 million and $175 million, respectively. In total, that makes 21 companies so far this year with nine-figure megarounds on the books. Much of the push is driven by investors who, in the boom years of 2020 and 2021, chased companies that hadn’t put their drugs into the clinic — only to get burned when those projects failed or have lingered in development for years. Now venture capitalists are seeking investments that can fund clinical proof-of-concept data, industry insiders told Endpoints News, which requires more financing. Data provided by DealForma showed that while funding sizes for very early-stage startups have been largely flat, money going toward companies in the clinic, in particular those in #Phase3, has risen substantially. Read more from #EndPointsNews 👇🏽 https://lnkd.in/dQU5W4Bu

Portfolio companies news 🏆 : Congratulations to our two portfolio companies DNA Script and ImCheck Therapeutics for being part of the French Tech Next40/120 program. 💡 DNA Script world leader in on-demand enzymatic DNA synthesis, confirms its place in the French Tech Next40. This appointment confirms DNA Script's dynamism and strong progress, particularly in R&D, recruitment and international expansion. 💡ImCheck Therapeutics is one of the few therapeutics-focused biotech and healthcare start-up/scale-up companies selected as one of the 120 companies. This highlights ImCheck as one of the leaders among the companies supporting the ambitions of the Innovation Santé 2030 plan. This ranking is a validation of their constant commitment to #innovation and #growth among the 120 most successful start-ups in France providing answers to the challenges of today and tomorrow. Xavier Godron Thomas Ybert Sylvain Gariel Pierre d'Epenoux and all the teams. #KurmaDiagnostics #KurmaGrowthOpportunities #KurmaBiofund #Startup #FrenchTech #Healthinnovation

🥇 I am beyond moved to win the W.A. De Vigier Stiftung award 🥇 One of the most emotional feelings in my life 💖 . When I was called out for the last winning prize as one of the six startups, my legs went weak and then it hit me that all the hard work pays off. Simon Ittig with his speech was just right. As a founder you will sometimes question the sense of running your startup, but you just need to trust the process and keep working. As André Hoffmann said that evening: never stop innovating! And this is our promise because the fascination for innovation is what drives us every day! I am extremely grateful to the entire De Vigier Foundation for the belief and the trust in the execution of Treeless Pack’s mission to replace fossil-based materials with bio-based cellulose materials using microorganisms. 🙏 A heartfelt thank you to the whole W.A. De Vigier Stiftung: The management - Hanna Byland, Carmen Lamparter The board - André Hoffmann Theresa Visarius Carolyn J. Lutz Alain Nicod Felix Grisard Wolfgang Heutschi Guy Petignat Pirmin Bischof The De Vigier Family The Selection experts - Christian Brand and Michael Sauter A shout-out goes also to the FERS Stiftung Last but not least, I would emphasize the importance of the whole journey of the competition. We created an amazing group of like-minded entrepreneurs that share the same values and hopefully beyond the prizes and the reputation, the competition will result in long- lasting relationships among the alumni! 🤝 Julia A. Carpenter apheros Alessandro Morra Ascento Kevin Yim, PhD EVIIVE Rajiv Singhal Grensol Group Aris Maroonian Neology Hydrogen Dr. Evan Petkov Optiml Anand V. PEROVSKIA SOLAR AG Mamta Chabria, PhD Tandem Therapeutics Jonas Wüst Tethys Robotics And finally, I would like to thank my amazing co-founder Patrycja Kucharczyk who has been at Treeless from the very beginning. Last: We are 🚀 FUNDRAISING 🚀, so if you want to invest in the future of bio-based materials please get in touch! 🌿 👨🔬 #innovation #motivation #award #DeVigier #founders #fundraising #sustainability #cleantech #materials

ICYMI: I sat down with FogPharma's new CEO Mathai Mammen, M.D., Ph.D. last week during #JPM24 to hear about his plans for the startup. One thing that stood out? He has no interest in pursuing an IPO or acquisition any time soon. Instead, he plans to raise Series E round — something you don't see very often in biotech, these days. #biotech #lifesciences #biopharma #financing #IPO #startups #startupstrategies #CEO #executiveleadership STAT

I learned that "big-pharma" despite it's perceived notoriety, conducts massively important life-saving research and drug development, alongside the bioscience startup community. Brilliant #FTLive Funding Biopharma Innovation panel with Bicycle Therapeutics, Bristol Myers Squibb, Syneos Health, and Cure. How can VCs join together with companies to commercially accelerate women & diverse led biopharma startups? #OverlookedVisionaries #Startups #Biopharma